BioRestorative Therapies Inc (BRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has a cash flow conversion efficiency ratio of -1.259x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.81 Million) by net assets ($3.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BRTX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
BioRestorative Therapies Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how BioRestorative Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioRestorative Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioRestorative Therapies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Logismos Information Systems S.A
AT:LOGISMOS
|
0.026x |
|
Trencor
JSE:TRE
|
0.000x |
|
Eifelhöhen-Klinik AG
F:EIF
|
-0.003x |
|
O.R.T.
TA:ORTC
|
-0.011x |
|
Maming Enam Sembilan Mineral Tbk PT
JK:AKSI
|
-0.008x |
|
Paratech Company Limited
KQ:033540
|
-0.044x |
|
Tonkens Agrar AG
XETRA:GTK
|
-0.032x |
|
PAKERS.Co.Ltd
KQ:065690
|
0.012x |
Annual Cash Flow Conversion Efficiency for BioRestorative Therapies Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of BioRestorative Therapies Inc from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see BRTX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $356.74K | $-10.79 Million | -30.243x | -3034.91% |
| 2024-12-31 | $8.53 Million | $-8.23 Million | -0.965x | -50.09% |
| 2023-12-31 | $10.00 Million | $-6.43 Million | -0.643x | -11.85% |
| 2022-12-31 | $10.29 Million | $-5.91 Million | -0.575x | -272.69% |
| 2021-12-31 | $21.60 Million | $-3.33 Million | -0.154x | -110.45% |
| 2020-12-31 | $-1.33 Million | $-1.96 Million | 1.475x | +172.42% |
| 2019-12-31 | $-12.78 Million | $-6.92 Million | 0.542x | -8.33% |
| 2018-12-31 | $-8.64 Million | $-5.10 Million | 0.591x | +4.80% |
| 2017-12-31 | $-6.84 Million | $-3.85 Million | 0.564x | -43.66% |
| 2016-12-31 | $-5.00 Million | $-5.00 Million | 1.000x | +25.25% |
| 2015-12-31 | $-3.91 Million | $-3.12 Million | 0.799x | +70.47% |
| 2014-12-31 | $-6.89 Million | $-3.23 Million | 0.469x | +17.22% |
| 2013-12-31 | $-6.69 Million | $-2.67 Million | 0.400x | -35.45% |
| 2012-12-31 | $-5.14 Million | $-3.18 Million | 0.619x | -18.78% |
| 2011-12-31 | $-3.69 Million | $-2.81 Million | 0.762x | -22.18% |
| 2010-12-31 | $-744.22K | $-729.22K | 0.980x | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more